ClinicalTrials.gg
CompletedNCT00878293Updated Jul 15, 2021

Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic

A Phase 2 interventional study of GRT6005 and MS Continus® in Diabetic Polyneuropathy, sponsored by Tris Pharma, Inc.. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Diabetic Neuropathies with a site in Germany — 3 open to participants now, 3 under way, 2 of them phase 3. Diabetic Neuropathies · Germany.

Enrollment
27th of 35
90 · median 189
Started
2009
with 2 others
Phase 2
14 of 37
none open now
Registered
15th of 37
by date
Lead sponsor
3 of 37
Tris Pharma, Inc.

Among the 37 studies in Diabetic Neuropathies with a site in Germany, this one is the 27th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2009, is one of 14 in phase 2, and was the 15th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

3 of the 37 studies in Diabetic Neuropathies with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Diabetic Neuropathies with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.

03

Conditions studied

  • Diabetic Polyneuropathy

Keywords

  • analgesic
  • diabetes mellitus
  • chronic neuropathic pain
  • painful polyneuropathy caused by diabetes mellitus type I or II
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with pain at least NRS >4 due to painful diabetic polyneuropaty.

Exclusion criteria

Exclusion Criteria:

  • to, or history of allergy or to morphine, fentanyl, hydrocodone, acetaminophen, heparin, polyethylene glycol 400 USP-NF or any compound planned to be used during the anesthesia, or their .
  • non Caucasian or Hispanic.
  • Concomitant painful disease.
  • Life-long history of seizure disorder or epilepsy.
  • Subjects with clinical relevant cardiac and vascular diseases.
  • Subjects with impaired renal function
  • Subjects with impaired hepatic function
  • Female subjects who are pregnant or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    A

    Dose 1, 40 µg

    Drug: GRT6005

  • Experimental
    B

    Dose 2, 120 µg

    Drug: GRT6005

  • Experimental
    C

    Dose 3

    Drug: GRT6005

  • Experimental
    D

    Dose 4

    Drug: GRT6005

  • Experimental
    E

    Dose 5

    Drug: GRT6005

  • Experimental
    F

    Dose 6

    Drug: GRT6005

  • Experimental
    G

    Dose 7

    Drug: GRT6005

  • Active comparator
    H

    Morphin

    Drug: MS Continus®

  • Placebo comparator
    I

    Placebo

    Drug: Placebo

Interventions

  • liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days

  • DrugMS Continus®

    60 mg, capsule, once daily

  • DrugPlacebo

    liquid formulation and capsule, once daily

06

What researchers measure

Primary outcomes

  1. Average daily pain intensity

    Time frame: 5 days

Secondary outcomes

  1. Quality of life Neuropathic pain scale Amount and first time of Rescue medication Adverse events, ECG, Laboratory values

    Time frame: 5 days

07

Study locations

4 sites
  • Investigator 3
    Bad Oeynhausen, Germany
  • Investigator 1
    Mainz, Germany
  • Investigator 2
    Münster, Germany
  • Investigator 4
    Manchester, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2009
First posted
Apr 8, 2009
Start
Apr 2009
Primary completionActual
May 2010
CompletionActual
May 2010
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00878293
Lead sponsor
Tris Pharma, Inc.
Responsible party
Sponsor
First posted
Apr 8, 2009
Start date
Apr 2009
Primary completion
May 2010
Completion
May 2010
Last update
Jul 15, 2021

Study contacts

Thomas Forst, Prof. Dr. med
principal investigator · IKFE, Parcusstr. 8, 55116 Mainz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion